Phase I trial and pharmacokinetic analysis of ifosfamide in cats with sarcomas

American Journal of Veterinary Research

Volumn 67, Issue 3, 2006, Pages 510-516

  Rassnick, Kenneth M ^a   Moore, Antony S ^b,d   Northrup, Nicole C ^b,e   Kristal, Orna ^b   Beaulieu, Bernard B ^c   Lewis, Lionel D ^c   Page, Rodney L ^a  

^a Department of Obstetrics Gynecology   (United States)

^b TUFTS UNIVERSITY   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^d Veterinary Oncology Consultants   (Australia)

^e UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; IFOSFAMIDE; MESNA; SODIUM CHLORIDE; ALKYLATING AGENT;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CANCER SURGERY; CAT DISEASE; COHORT ANALYSIS; CORRELATION COEFFICIENT; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG STRUCTURE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HEMORRHAGIC CYSTITIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; SARCOMA; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; VOMITING; ANIMAL; ANIMAL DISEASE; CAT; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; CLINICAL TRIAL; HALF LIFE TIME; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL;

ANIMALIA;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; CAT DISEASES; CATS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; IFOSFAMIDE; MALE; MODELS, CHEMICAL; MOLECULAR STRUCTURE; SARCOMA;

EID: 33646372989     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.67.3.510     Document Type: Article

References (30)

1. Mace JR, Keohan ML, Bernardy H, et al. Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide. Clin Cancer Res 2003;9:5829-5834.
2. Sarosy G. Ifosfamide - pharmacologic overview. Semin Oncol 1989;16:2-8.
3. Chen CS, Lin JT, Goss KA, et al. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Mol Pharmacol 2004;65:1278-1285.
4. Karle P, Renner M, Salmons B, et al. Necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide. Cancer Gene Ther 2001;18:220-230.
5. Loehrer PJ Sr. The history of ifosfamide. Semin Oncol 1992;19:2-6.
6. Hortobagyi GN. Activity of ifosfamide in breast cancer. Semin Oncol 1992;19:36-41.
7. Kaijser GP, Beijnen JH, Bult A, et al. Ifosfamide metabolism and pharmacokinetics (review). Anticancer Res 1994;14:517-531.
8. Barnett D. Preclinical toxicology of ifosfamide. Semin Oncol 1982;9:8-13.
9. Cohen MH, Creaven PJ, Tejada F, et al. Phase I clinical trial of isophosphamide (NSC-109724). Cancer Chemother Rep 1975;59:751-755.
10. Rassnick KM, Frimberger AE, Wood CA, et al. Evaluation of ifosfamide for treatment of various canine neoplasms. J Vet Intern Med 2000;14:271-276.
11. Rassnick KM, Gieger TL, Williams LE, et al. Phase I evaluation of CCNU (lomustine) in tumor-bearing cats. J Vet Intern Med 2001;15:196-199.
12. Burton LC, James CA. Rapid method for the determination of ifosfamide and cyclophosphamide in plasma by high-performance liquid chromatography with solid-phase extraction. J Chromatogr 1988;431:450-454.
13. Elias AD, Eder JP, Shea T, et al. High-dose ifosfamide with mesna uroprotection: a phase I study. J Clin Oncol 1990;8:170-178.
14. Lokich I, Anderson N, Bern M, et al. Ifosfamide continuous infusion without mesna. A phase I trial of a 14-day cycle. Cancer 1991;67:883-885.
15. Carli M, Passone E, Perilongo G, et al. Ifosfamide in pediatric solid tumors. Oncology 2003;65(suppl 2):99-104.
16. Cerny T, Leyvraz S, von Briel T, et al. Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1999;10:1087-1094.
17. Kerbusch T, de Kraker J, Keizer HJ, et al. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet 2001;40:41-62.
18. Boddy AV, Cole M, Pearson AD, et al. The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion. Cancer Chemother Pharmacol 1995;36:53-60.
19. Lewis LD, Fitzgerald DL, Harper PG, et al. Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism. Br J Clin Pharmacol 1990;30:725-732.
20. Chauret N, Gauthier A, Martin J, et al. In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse. Drug Metab Dispos 1997;25:1130-1136.
21. Pass GJ, Carrie D, Boylan M, et al. Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome p450 reductase null mouse. Cancer Res 2005;65:4211-4217.
22. Klastersky J. Side effects of ifosfamide. Oncology 2003;65(suppl 2):7-10.
23. Rassnick KM, Rodriguez CO, Khanna C, et al. Results of a phase II clinical trial on the use of ifosfamide for treatment of cats with vaccine-associated sarcomas. Am J Vet Res 2006;67:517-523.
24. Aleksa K, Ito S, Koren G. Renal-tubule metabolism of ifosfamide to the nephrotoxic chloroacetaldehyde: pharmacokinetic modeling for estimation of intracellular levels. J Lab Clin Med 2004;143:159-162.
25. Crow SE, Theilen GH, Madewell BR, et al. Cyclophosphamide-induced cystitis in the dog and cat. J Am Vet Med Assoc 1977;171:259-262.
26. Henness AM. Treatment of cyclophosphamide-induced cystitis. J Am Vet Med Assoc 1985;187:4-5.
27. Furlanut M, Franceschi L. Pharmacology of ifosfamide. Oncology 2003;65(suppl 2):2-6.
28. Weiss RB. Hypersensitivity reaction to cancer chemotherapy. Semin Oncol 1982;9:5-13.
29. Frustaci S, De Paoli A, Bidoli E, et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology 2003;65(suppl 2):80-84.
30. Antman KH, Ryan L, Elias A, et al. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 1989;7:126-131.